Statements (25)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:clinical_trial
|
| gptkbp:ageRange |
18 Years and older
|
| gptkbp:clinicalTrialPhase |
Phase 2
|
| gptkbp:completedIn |
December 2022
|
| gptkbp:condition |
Asthma
|
| gptkbp:enrollment |
120
|
| gptkbp:gender |
All
|
| https://www.w3.org/2000/01/rdf-schema#label |
NCT04150497
|
| gptkbp:intervention |
gptkb:Placebo
gptkb:Tezepelumab Parallel Assignment |
| gptkbp:location |
gptkb:Canada
gptkb:Japan gptkb:United_States |
| gptkbp:mask |
Double (Participant, Investigator)
|
| gptkbp:officialName |
A Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Tezepelumab in Adults With Severe, Uncontrolled Asthma
|
| gptkbp:purpose |
Treatment
|
| gptkbp:result |
Change from baseline in Asthma Control Questionnaire (ACQ-6) score at Week 24
|
| gptkbp:secondaryOutcome |
Change from baseline in pre-bronchodilator FEV1 at Week 24
|
| gptkbp:sponsor |
gptkb:AstraZeneca
|
| gptkbp:startDate |
November 2019
|
| gptkbp:status |
Completed
|
| gptkbp:studyType |
Interventional
|
| gptkbp:bfsParent |
gptkb:UCART22
|
| gptkbp:bfsLayer |
8
|